<DOC>
	<DOCNO>NCT01093664</DOCNO>
	<brief_summary>This phase IB follow-up study ass boost immunization AFFITOPE AD02 regard safety/tolerability , immunological clinical activity Alzheimer patient receive vaccine within clinical study AFF002 .</brief_summary>
	<brief_title>Safety/Tolerability , Immunological Clinical Activity Boost Immunization With AFFITOPE AD02</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Participation AFF002 AFF004 Presence history allergy component vaccine , consider relevant investigator Contraindication MRI image History and/or presence autoimmune disease , consider relevant investigator Active infectious disease ( e.g. , Hepatitis B , C ) Presence and/or history Immunodeficiency ( e.g. , HIV ) Significant systemic illness</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2010</verification_date>
</DOC>